Epigenomic Analysis Reveals a Unique DNA Methylation Program of Metastasis-Competent Circulating Tumor Cells in Colorectal Cancer

UDC.coleccionInvestigaciónes_ES
UDC.departamentoMatemáticases_ES
UDC.grupoInvModelización, Optimización e Inferencia Estatística (MODES)es_ES
UDC.journalTitleScientific Reportses_ES
UDC.startPage15401es_ES
UDC.volume13es_ES
dc.contributor.authorBao-Caamano, Aida
dc.contributor.authorCosta-Fraga, Nicolás
dc.contributor.authorCayrefourcq, Laure
dc.contributor.authorJácome, M. A.
dc.contributor.authorRodríguez-Casanova, Aitor
dc.contributor.authorMuinelo Romay, Laura
dc.contributor.authorLópez-López, Rafael
dc.contributor.authorAlix-Panabières, Catherine
dc.contributor.authorDíaz-Lagares, Ángel
dc.date.accessioned2023-10-16T08:53:23Z
dc.date.available2023-10-16T08:53:23Z
dc.date.issued2023-09-16
dc.description.abstract[Abstract] Circulating tumor cells (CTCs) and epigenetic alterations are involved in the development of metastasis from solid tumors, such as colorectal cancer (CRC). The aim of this study was to characterize the DNA methylation profile of metastasis-competent CTCs in CRC. The DNA methylome of the human CRC-derived cell line CTC-MCC-41 was analyzed and compared with primary (HT29, Caco2, HCT116, RKO) and metastatic (SW620 and COLO205) CRC cells. The association between methylation and the transcriptional profile of CTC-MCC-41 was also evaluated. Differentially methylated CpGs were validated with pyrosequencing and qMSP. Compared to primary and metastatic CRC cells, the methylation profile of CTC-MCC-41 was globally different and characterized by a slight predominance of hypomethylated CpGs mainly distributed in CpG-poor regions. Promoter CpG islands and shore regions of CTC-MCC-41 displayed a unique methylation profile that was associated with the transcriptional program and relevant cancer pathways, mainly Wnt signaling. The epigenetic regulation of relevant genes in CTC-MCC-41 was validated. This study provides new insights into the epigenomic landscape of metastasis-competent CTCs, revealing biological information for metastasis development, as well as new potential biomarkers and therapeutic targets for CRC patients.es_ES
dc.description.sponsorshipThis research was funded by the ISCIII (PI18/00307) and the European Regional Development Fund (FEDER), and by the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. We would like to thank all donors who participated in the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. AB-C is funded by a predoctoral contract PFIS (FI19/00240) from “Instituto de Salud Carlos III” (ISCIII) co-funded by “Fondo Social Europeo” (FSE). NC-F is funded by a predoctoral contract from “Xunta de Galicia” (IN606A-2020/004). AR-C is supported by the Roche-Chus Joint Unit (IN853B 2018/03) funded by “Axencia Galega de Innovación (GAIN), Vicepresidencia Segunda e Consellería de Economía, Empresa e Innovación”. LM-R is funded by a contract “Miguel Servet” from ISCIII (CP20/00129). CA-P is supported by funding from the European Union Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie grant agreement No. 765492, by The National Institute of Cancer (INCa, http://www.e-cancer.fr), SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, and the ERA-NET TRANSCAN 2 JTC 2016 PROLIPSY, la Fondation ARC pour la Recherche sur le cancer and les Fonds de dotation AFER pour la recherche médicale. AD-L was funded by a contract “Juan Rodés” (JR17/00016) from “Instituto de Salud Carlos III” (ISCIII) and by Servizo Galego de Saúde (SERGAS). All authors have read the journal's policy on disclosure of potential conflicts of interest, and have disclosed any financial or personal relationship with organizations that could potentially be perceived as influencing the described researches_ES
dc.description.sponsorshipXunta de Galicia; IN606A-2020/004es_ES
dc.description.sponsorshipXunta de Galicia; IN853B 2018/03es_ES
dc.description.sponsorshipFrancia. Institut National du Cancer; INCa_Inserm_DGOS_12553es_ES
dc.identifier.citationBao-Caamano, A., Costa-Fraga, N., Cayrefourcq, L. et al. Epigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer. Sci Rep 13, 15401 (2023). https://doi.org/10.1038/s41598-023-42037-wes_ES
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/2183/33770
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/PI18%2F00307/ES/DESARROLLO DE UNA FIRMA EPIGENETICA EN BIOPSIA LIQUIDA PARA PREDECIR LA RESPUESTA TERAPEUTICA EN CANCER COLORRECTAL METASTASICOes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/765492es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/FI19%2F00240/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/CP20%2F00129/ES/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/JR17%2F00016/ES/
dc.relation.urihttps://doi.org/10.1038/s41598-023-42037-wes_ES
dc.rightsAtribución 4.0 Internacionales_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleEpigenomic Analysis Reveals a Unique DNA Methylation Program of Metastasis-Competent Circulating Tumor Cells in Colorectal Canceres_ES
dc.typejournal articlees_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione629ebcc-3475-4638-b4e7-bf3e786f997c
relation.isAuthorOfPublication.latestForDiscoverye629ebcc-3475-4638-b4e7-bf3e786f997c

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Jacome_MA_2023_Epigenomic_analysis_reveals_unique_DNA_methylation_program.pdf
Size:
1.7 MB
Format:
Adobe Portable Document Format
Description:
Loading...
Thumbnail Image
Name:
Jacome_MA_2023_Correction_Epigenomic_analysis_reveals_unique_DNA_methylation_program.pdf
Size:
1.49 MB
Format:
Adobe Portable Document Format
Description: